Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain, the CRIVERVA study

  • Trapero Bertrán, Marta
  • Acera Pérez, Amelia
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Manresa, J. M|||0000-0001-8306-5798
  • Rodríguez Capriles, Diego
  • Rodríguez Martínez, Ana
  • Bonet Simó, Josep Maria|||0000-0002-7981-5880
  • Sánchez Sánchez, Norman
  • Hidalgo Valls, Pablo
  • Díaz Sanchís, Mireia
The aim of the study is to carry out a cost-effectiveness analysis of three different interventions to promote the uptake of screening for cervical cancer in general practice in the county of Valles Occidental, Barcelona, Spain. Women aged from 30 to 70 years (n = 15,965) were asked to attend a general practice to be screened. They were randomly allocated to one of four groups: no intervention group (NIG); one group where women received an invitation letter to participate in the screening (IG1); one group where women received an invitation letter and informative leaflet (IG2); and one group where women received an invitation letter, an informative leaflet and a phone call reminder (IG3). Clinical effectiveness was measured as the percentage increase in screening coverage. A cost-effectiveness analysis was performed from the perspective of the public health system with a time horizon of three to five years - the duration of the randomised controlled clinical trial. In addition, a deterministic sensitivity analysis was performed. Results are presented according to different age groups. The incremental cost-effectiveness ratio (ICER) for the most cost-effective intervention, IG1, compared with opportunistic screening was € 2.78 per 1% increase in the screening coverage. The age interval with the worst results in terms of efficiency was women aged < 40 years. In a population like Catalonia, with around 2 million women aged 30 to 70 years and assuming that 40% of these women were not attending general practice to be screened for cervical cancer, the implementation of an intervention to increase screening coverage which consists of sending a letter would cost on average less than € 490 for every 1000 women. ClinicalTrials.gov Identifier: . The online version of this article (doi:10.1186/s12889-017-4115-0) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The use of HPV16-E5, EGFR, and PEGFR as prognostic biomarkers for oropharyngeal cancer patients

  • Taberna, Miren|||0000-0002-2446-186X
  • Torres Tarrés, Montserrat
  • Alejo, María
  • Mena, Marisa|||0000-0003-2163-892X
  • Tous, Sara|||0000-0002-5423-7092
  • Marquez, Sandra
  • Pavón, Miquel A.
  • León, Xavier|||0000-0002-8393-2721
  • Garcia Lorenzo, J.|||0000-0002-6123-7808
  • Guix, Marta|||0000-0002-2143-0697
  • Hijano, Rafael|||0000-0001-6787-5440
  • Bonfill Abella, Teresa|||0000-0003-2775-0293
  • Aguilà, Antón
  • Lozano, Alicia|||0000-0003-0528-5212
  • Mesia, Ricard|||0000-0002-3785-3563
  • Alemany, Laia|||0000-0003-0945-6015
  • Bravo, Ignacio G.
Anti-epidermal-growth-factor-receptor (EGFR) therapies in combination with radiotherapy are being studied on deescalation clinical trials for HPV-related oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling of activated EGFR to the cell surface, enhancing factor signal transduction. Our aim was to evaluate viral HPV16-E5 oncogene expression as well as EGFR and phosphorylated-EGFR (pEGFR), protein levels as biomarkers for clinical outcome in a retrospective cohort of OPC patients. Formalin-fixed-paraffin-embedded OPCs were collected from 1990 to 2013. OPC samples containing HPV-DNA were subject to viral E6*I mRNA detection and p16INK4a immunohistochemistry (IHC). HPV16-positive cases were evaluated for HPV16-E5 (RT-PCR) and EGFR/pEGFR (IHC). A stratified and matched random sample of HPV-negative samples was used as control and evaluated for EGFR/pEGFR. Overall survival (OS) and disease free survival (DFS) estimates were assessed for locally advanced OPC patients (stage III, IVa,b 7th edition). Among 788 OPC patient samples, 53 were double positive for HPV16-DNA/p16. HPV16-E5 expression was found in 41 of 53 samples (77.4%). EGFR expression was observed in 37.7 vs 70.8% of HPV16-positive vs HPV-negative samples, respectively; (adjusted OR = 0.15) 5% CI = 0.04-0.56]). Expression of pEGFR followed an inverse pattern with 39.6 and 24.9% detection in HPV16-positive and HPV-negative samples; (adjusted OR = 1.58 [95% CI = 0.48-5.17]). Within HPV16-positive cases, no association between HPV16-E5/EGFR nor pEGFR was observed. With a median follow-up of 39.36 months (min = 0.03 - max = 272.07), the combination of HPV status and EGFR or pEGFR expression were predictors of better OS (p < 0.001, for both) and DFS (p < 0.001 for EGFR and p = 0.003 for pEGFR). HPV16-E5 is highly expressed on HPV16-positive OPCs. Interestingly, HPV16-positive cases expressed significantly more pEGFR while HPV-negative cases expressed more EGFR. The combinations of HPV status and EGFR or pEGFR may be useful biomarkers for evaluating prognosis outcome in OPC patients.